PROFUSA INC

PROFUSA CFO converts debt to equity at $4.28, boosting insider confidence and setting the stage for a potential reverse split‑driven rally.

Profusa Inc. faces a strategic reverse‑stock‑split after HRT Financial’s rapid sell‑off, raising investor interest, liquidity concerns, and future value potential.

HRT FINANCIAL LP’s recent Profusa sell‑off highlights the strategic timing around its planned reverse‑stock‑split, offering insights into investor sentiment and the company’s future trajectory.

Profusa’s $1.87 M convertible note conversion into 5.34 M shares injects equity, fuels regulatory progress, and positions the biotech for a public or merger move—watch capital use and insider activity.

Profusa’s CFO converts a $1.87 M debt into 5.34 M shares at $0.35 each, cutting leverage, boosting equity, and signaling a strategic shift toward acquisitions and a new $100 M cash line.

Profusa insider buying signals growth optimism as executives stack shares, driving confidence in its health‑care analytics platform and potential upside for investors.

Profusa’s zero‑cost insider share deal and new Lumee digital‑health platform could spark growth—see how equity, AI analytics, and value‑based care may boost value, not dilute shareholders.